Health-related quality of life following TAVI or cardiac surgery in patients at intermediate and low risk: a systematic review and meta-analysis

Gonnah, Ahmed R., Abdelwahab, Mohamed, Taylor, Rebecca ORCID: https://orcid.org/0000-0003-3429-3123, Labib, Aser, Masoud, Omar, Debski, Maciej ORCID: https://orcid.org/0000-0002-3669-3916, Abdelaziz, Hesham Kamal and Roberts, David Hesketh (2023) Health-related quality of life following TAVI or cardiac surgery in patients at intermediate and low risk: a systematic review and meta-analysis. Clinical Medicine, 23 (6). pp. 594-605. ISSN 1470-2118

[thumbnail of 1-s2.0-S1470211824000320-main]
Preview
PDF (1-s2.0-S1470211824000320-main) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (560kB) | Preview

Abstract

Recent randomised trials have shown that clinical outcomes with transcatheter aortic valve implantation (TAVI) are non-inferior to surgical aortic valve replacement (SAVR) in patients with symptomatic aortic stenosis at intermediate to low risk. Health-related quality of life (HrQoL) outcomes in these patient groups remain uncertain. A systematic search of the literature was conducted that included nine trials and 11,295 patients. Kansas City Cardiomyopathy Questionnaire (KCCQ), a heart-failure-specific measure and EuroQol-5D (EQ-5D) (a generic health status tool) changes were the primary outcomes. New York Heart Association (NYHA) classification was the secondary outcome. Improvement in KCCQ scores was greater with TAVI (mean difference (MD)=13.56, 95% confidence interval (CI) 11.67–15.46, p<0.001) at 1 month, as was the improvement in EQ-5D (MD=0.07, 95% CI 0.05–0.08, p<0.001). There was no difference in KCCQ (MD=1.05, 95% CI −0.11 to 2.21, p=0.08) or EQ-5D (MD=–0.01, 95% CI −0.03 to 0.01), p=0.37) at 12 months. NYHA functional class 3/4 was lower in patients undergoing TAVI at 1 month (MD=0.51, 95% CI 0.34–0.78, p=0.002), but there was no difference at 12 months (MD=1.10; 95% CI 0.87–1.38, p=0.43). Overall, TAVI offers early benefit in HRQoL outcomes compared with SAVR, but they are equivalent at 12 months.

Item Type: Article
Uncontrolled Keywords: eq-5d,kccq,nyha,savr,tavi,aortic stenosis,medicine(all) ,/dk/atira/pure/subjectarea/asjc/2700
Faculty \ School: Faculty of Science > School of Biological Sciences
Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 25 Mar 2024 15:30
Last Modified: 03 Apr 2024 09:31
URI: https://ueaeprints.uea.ac.uk/id/eprint/94752
DOI: 10.7861/clinmed.2023-0258

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item